The U.S. Food and Drug Administration granted approval to Jascayd (nerandomilast), a preferential PDE4B inhibitor developed by Boehringer Ingelheim, for idiopathic pulmonary fibrosis (IPF). The approval, the first new FDA nod in IPF in over a decade, follows phase III data showing a slowing of lung‑function decline versus placebo and a tolerability profile that may differ from incumbent therapies. Boehringer has a long track record in IPF and will position Jascayd as an oral alternative to existing antifibrotics. Analysts see the approval as a modest but meaningful advance that could renew commercial and clinical interest in the IPF space.